CKLIFE SCIENCES has announced the formation of its wholly-owned subsidiary, Sequencio Therapeutics Company Limited. The new entity will be dedicated to accelerating the development of the company's therapeutic cancer vaccine portfolio. The establishment of Sequencio consolidates these research projects onto a single, focused platform, reflecting the company's strategic commitment to expanding in the emerging field of cancer immunotherapy.

Sequencio will concentrate on developing therapeutic vaccines designed to activate a patient's own immune system to fight cancer cells. The goal is to achieve durable and stable disease remission while maintaining a favorable safety profile, thereby addressing key limitations of existing standard therapies. The long-term vision for Sequencio is to redefine cancer treatment paradigms, shifting the focus from inducing temporary tumor shrinkage to achieving long-term, controlled remission through the immune system.

Vaccine research and design will be conducted by an internal team, leveraging both in-house scientific expertise and collaborations with external partners to expedite the overall development timeline. Sequencio's preclinical portfolio includes the company's investigational cancer vaccine targeting Trophoblast Cell Surface Antigen 2 (TROP2). In preclinical studies involving mouse models of breast cancer and colorectal cancer, this candidate vaccine successfully induced a potent T-cell immune response and demonstrated 100% efficacy in suppressing tumor growth.

Furthermore, the portfolio also includes other candidate vaccines targeting antigens such as PRAME, PD-L1, the B7-H3 immune checkpoint, and the Claudin 6 protein. With its holdings in Sequencio, TransCode, and Dogwood, CKLIFE SCIENCES has established a research and development platform. This platform supports a diverse pipeline of early and late-stage projects focused on areas with significant unmet medical needs.